Overview
- Texas asked the court to halt a Nov. 26 dividend of roughly $398–$400 million and to temporarily stop Kenvue and Johnson & Johnson from advertising Tylenol as safe for pregnant women and young children.
- The filings follow Paxton’s lawsuit alleging deceptive marketing for failing to warn that prenatal acetaminophen use may be linked to autism and ADHD, claims the companies dispute.
- Kenvue says the state’s theories lack legal merit and scientific support and vows to defend the safety of its products and the underlying science.
- The requests cite recent federal guidance urging caution during pregnancy without establishing causation, while major medical groups criticized that guidance as premature.
- No hearing has been set on the injunctions, and the effort to block the payout adds uncertainty to Kimberly-Clark’s planned acquisition as Kenvue shares trade well below the announced deal price.